Transaction · 0001104659-26-104404
QNRXQuoin Pharmaceuticals, Ltd.
Myers Michael
Myers Michael, CEO, reported an open-market or private purchase at Quoin Pharmaceuticals, Ltd. involving 10245.000000 shares. Reported holdings after the transaction were 10245.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Open-market buySEC transaction code PCEO
- Trade date
- Aug 31, 2026
- Filing date
- Sep 02, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingmissing priceThe filing did not provide a usable price per share.
QNRX price since this filing
Daily closing prices, with the filing date and available return windowsQNRX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -34.0%1w ago -19.6%1d ago -20.2%
Returns since7d +3.4%30d -30.0%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Buy Code P
- Identifier
- 0001104659-26-104404 Ordinary Warrants (Right to Buy)
- Transaction date
- Aug 31, 2026 Filed Sep 02, 2026, 01:39 AM · 2d delay
- Shares
- 10,245 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 10,245 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
CEO Buy Cluster Buy Derivative Transaction Director Buy Direct Ownership Large Holdings Increase
Filing-only score
+32 points
Compact filing score computed from stored Form 4 facts. Version v1.
Strong filing signal
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
How this score is calculated
- open_market_purchase+12 points
transaction_code = P
Code P is a discretionary open-market purchase. - direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - ceo_buy+12 points
is_officer + officer_title/role mentions CEO
CEO open-market purchase. - cluster_buy+14 points
cluster-buy signal matched
Multiple insiders bought within the configured window. - large_holdings_increase+8 points
large-holdings-increase signal matched
Reported acquired shares meet the configured percentage of post-transaction holdings. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
Missing facts
Read the scoring methodology- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Executive Officer
Officer YesDirector Yes10% NoOther No
Footnotes & amended
- F1
Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2
Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
- F3
The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.
- F4
The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical tr…
Related transactions
Same SEC filing0 other transactions
Recent company activity
QNRX0 recent txs